
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics NV is positioned for potential stock price appreciation given the possibility of advancing its pipeline products into clinical trials more swiftly than expected, which could yield proof of concept data in humans. The company's Axiomer RNA base-editing platform is viewed as a promising asset, with anticipation surrounding upcoming clinical data from the first-in-human study of its lead candidate. Additionally, the management's assertion that the current cash position is adequate to sustain operations until mid-2027 provides financial stability, bolstering investor confidence in the company's future endeavors.
Bears say
ProQR Therapeutics NV reported a net loss of -€12.2 million for the quarter, significantly widening from a loss of -€2.7 million in the same period in the previous year, indicating worsening financial performance. The company's reliance on the outcomes of ongoing Phase Ib/II/III studies presents inherent risks, as negative results could exert downward pressure on its stock value. Additionally, advancements in competitor treatment methods pose a threat to the company’s existing therapies, potentially rendering them non-competitive or obsolete.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares